Open access
Open access
Powered by Google Translator Translator

RCT: Comparison of Valproate vs. Levetiracetam for newly diagnosed generalized and unclassifiable epilepsy shows Valproate should remain the first-line treatment option

12 Apr, 2021 | 00:52h | UTC

The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial – The Lancet

Commentary: Clinical trials assess best first-line drugs for epilepsy – University of Liverpool

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.